PML and leukemia: Moreover, the re-establishment of PML bodies induced senescence of leukemia cells but not of normal bone marrow progenitors in vivo.123 More recently, it has been shown that restoring PML body formation by ATO in JAK2V617F myeloproliferative neoplasms could be beneficial in combination with standard therapies.125 Collectively, these findings suggest that restoring tumor suppressive biomolecular condensates, such as PML bodies could provide a powerful therapeutic strategy that is not restricted to APL but would likely be also effective in other myeloid malignancies (Figure 3D).